Please note that following on from information provided to NICE by the company in January 2024, the appraisal was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 4052
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 29 January 2025 | Discontinued. Please note that following on from information provided to NICE by the company in January 2024, the appraisal was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued |
| 21 June 2024 | Suspended. For information, the company have announced that Tecentriq did not meet its primary endpoint during the Phase 3 trial and therefore they will no longer be pursuing a Marketing Authorisation Application in this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties as and when the situation changes. |
| 02 November 2023 | Note - Note added to the project documents |
| 30 March 2023 | Note added to the project documents |
| 19 December 2022 | Note added to the project documents |
For further information on our processes and methods, please see our CHTE processes and methods manual